DRP1: at the crossroads of dysregulated mitochondrial dynamics and altered cell signaling in cancer cells
A Adhikary, A Mukherjee, R Banerjee, S Nagotu - ACS omega, 2023 - ACS Publications
In the past decade, compelling evidence has accumulated that highlights the role of various
subcellular structures in human disease conditions. Dysregulation of these structures greatly …
subcellular structures in human disease conditions. Dysregulation of these structures greatly …
[HTML][HTML] ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated …
YQ Ao, J Gao, C Jin, S Wang, LC Zhang… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Activating signal cointegrator 3 (ASCC3) has been identified as an oncogenic
factor that impairs host immune defense. However, the underlying mechanisms of …
factor that impairs host immune defense. However, the underlying mechanisms of …
[HTML][HTML] Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated with Immunotherapy in The Netherlands
AL Noordhof, EM Swart, RAM Damhuis… - JTO Clinical and …, 2023 - Elsevier
Introduction With the approval of G12C inhibitors as the second line of treatment for KRAS
G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to …
G12C-mutated NSCLC, and the expanding research regarding targeting KRAS, it is key to …
The efficacy of immune checkpoint inhibitors vs. chemotherapy for KRAS‐mutant or EGFR‐mutant non‐small‐cell lung cancers: a meta‐analysis based on …
W Chen, L Li, S Cheng, J Yu - Disease Markers, 2022 - Wiley Online Library
Importance. Following the research, we discovered that other meta‐analyses contained
incomplete genes or did not include a sufficient number of trials. To address these …
incomplete genes or did not include a sufficient number of trials. To address these …
[HTML][HTML] Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
M Wang, L Zhu, X Yang, J Li, Y Liu… - Frontiers in …, 2023 - frontiersin.org
Lung cancer is the common malignant tumor with the highest mortality rate. Lung cancer
patients have achieved benefits from immunotherapy, including immune checkpoint …
patients have achieved benefits from immunotherapy, including immune checkpoint …
[HTML][HTML] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real …
Background KRAS mutations occur frequently in advanced non-small cell lung cancer
(aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11 or KEAP1 …
(aNSCLC); the G12C mutation is the most prevalent. Alterations in STK11 or KEAP1 …
[HTML][HTML] From targeted therapy to a novel way: Immunogenic cell death in lung cancer
J Xu, Y Xiong, Z Xu, H Xing, L Zhou, X Zhang - Frontiers in Medicine, 2022 - frontiersin.org
Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer
mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of …
mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of …
[HTML][HTML] Identification of prognosis-related lncRNAs and cell validation in lung squamous cell carcinoma based on TCGA data
Y Cui, Y Wu, M Zhang, Y Zhu, X Su, W Kong… - Frontiers in …, 2023 - frontiersin.org
Objective To discern long non-coding RNAs (lncRNAs) with prognostic relevance in the
context of lung squamous cell carcinoma (LUSC), we intend to predict target genes by …
context of lung squamous cell carcinoma (LUSC), we intend to predict target genes by …
Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity
H Zhao, L Li, J Liu, R Mai, J Chen, J Chen - Bioorganic Chemistry, 2022 - Elsevier
KRas is the most frequently mutated protein of the three Ras isoforms in various cancer
types. KRas mutations (ie G12C) are present in approximately 30% of human cancers …
types. KRas mutations (ie G12C) are present in approximately 30% of human cancers …
[HTML][HTML] 1265P IMpower150: a post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
H West, F Cappuzzo, M Reck, T Mok… - Annals of …, 2020 - annalsofoncology.org
Background Mutations in the KRAS oncogene and STK11 and KEAP1 tumour suppressor
genes are found in non-squamous NSCLC, frequently co-occur and lead to differential …
genes are found in non-squamous NSCLC, frequently co-occur and lead to differential …